Dexcom (Nasdaq:DXCM) announced that it teamed up with RxFood on a digital diabetes solution for people in Canada. The first-of-its-kind partnership combines Dexcom’s continuous glucose monitoring (CGM) with RxFood’s AI-driven personalized nutrition assessments. The companies aim to introduce an improved digital health solution for people living with diabetes. It integrates food data with insulin dosing, […]
Business/Financial News
Abbott completes Bigfoot Biomedical acquisition
Abbott (NYSE:ABT) announced today that it completed its previously announced acquisition of Bigfoot Biomedical. Pursuant to the terms of the merger agreement, upon completion, Bigfoot became a wholly-owned subsidiary of Abbott. The companies declined to disclose financial terms. Abbott announced on Sept. 5 that it entered into a definitive agreement to acquire the smart insulin management […]
Medtronic wins CE mark for next-gen Simplera CGM with InPen integration
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its new Simplera continuous glucose monitor (CGM). The all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Medtronic’s newest no-fingerstick sensor eliminates the need for overtape, too. It seamlessly integrates with the InPen smart insulin […]
FDA requests more info on neffy needle-free epinephrine
ARS Pharmaceuticals (Nasdaq:SRPY) says the FDA issued a complete response letter (CRL) regarding its neffy epinephrine nasal spray. The offering covers the emergency treatment of severe type I allergic reactions in children and adults weighing 30 kg (66 pounds) or more. The company initially set an anticipated target action date of mid-2023 for its PDUFA […]
Ypsomed concludes autoinjector supply deal with Novo Nordisk
Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its […]
Elutia raises $26M for drug-eluting biomatrix tech
Elutia (Nasdaq:ELUT) announced today that it entered into a securities purchase agreement worth total proceeds of $26.2 million. The drug-eluting biomatrix company expects the private placement financing to result in initial gross proceeds of approximately $10.5 million. The full exercise of warrants would add $15.8 million to reach a total of $26.2 million. Silver Spring, […]
Abbott, WeightWatchers unveil connected diabetes app
Abbott (NYSE:ABT) and WeightWatchers today announced the availability of a connected app for people living with diabetes. In August 2022, the companies announced a collaboration to integrate continuous glucose monitoring (CGM) with the WW diabetes-tailored plan. The integrated offering provides a mobile experience with information and insights needed for those with diabetes. It helps to […]
Dexcom One CGM sensor launches in France with reimbursement
Dexcom (Nasdaq:DXCM) recently announced the availability of its Dexcom One real-time continuous glucose monitor (CGM) in France. The availability of the real-time CGM sensor comes via reimbursement. It brings the technology to half a million more people with diabetes in France. The company secured access to the platform for all patients two years and older […]
Vaxess raises $9M to support shelf-stable vaccine patch
Vaxess Technologies announced today that it raised an additional $9 million in venture capital funding to support its vaccine delivery technology. Cambridge, Massachusetts-based Vaxess develops a shelf-stable vaccine patch with the potential for self-application. The company’s MiMix system features sustained-release technology for administering vaccines and therapeutics. For vaccines, its controlled release simulates the pace of […]
Bausch+Lomb launches $1.4B offering to finance XIIDRA eye drop buy
Bausch + Lomb (NYSE:BLCO) announced today that it launched an offering worth $1.4 billion in new senior secured notes. The company intends to offer the notes, due 2028, and to enter into an incremental term loan facility. Both moves aim to support the financing of the company’s pending acquisition of XIIDRA. Bausch + Lomb expects […]
